Medicinal chemistry and pharmacological effects of farnesoid x receptor (Fxr) antagonists

Current Topics in Medicinal Chemistry

Volumn 14, Issue 19, 2014, Pages 2188-2205

  Lamers, Christina ^a   Schubert Zsilavecz, Manfred ^a   Merk, Daniel ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Atherosclerosis; Cancer; FXR antagonists; FXR knockout; Glucose homeostasis; Guggulsterone; Lipid homeostasis; Liver disorders; Metabolic disorders; Selective bile acid receptor modulators (SBARMs)

Indexed keywords

3 [2 [2 CHLORO 4 [3 (2,6 DICHLOROPHENYL) 5 ISOPROPYL 4 ISOXAZOLYLMETHOXY]PHENYL]VINYL]BENZOIC ACID; BETA CATENIN; CHENODEOXYCHOLIC ACID; CYCLIN D1; ESTROGEN RECEPTOR; FARNESOID X RECEPTOR ANTAGONIST; GLUTATHIONE TRANSFERASE ALPHA; GLUTATHIONE TRANSFERASE M3; GUGGULSTERONE; HEME OXYGENASE 1; INTERLEUKIN 6; INTERLEUKIN 8; JANUS KINASE 2; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MESSENGER RNA; METALLOTHIONEIN I; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RECEPTOR BLOCKING AGENT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); SELECTIVE ESTROGEN RECEPTOR MODULATOR; STAT3 PROTEIN; SURVIVIN; SUVANINE; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG; WNT PROTEIN; CELL RECEPTOR; DRUG; FARNESOID X-ACTIVATED RECEPTOR;

ARTICLE; ATHEROSCLEROSIS; BILE ACID SYNTHESIS; CANCER PROGNOSIS; CARCINOGENESIS; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; DOWN REGULATION; HISTOLOGY; HUMAN; IC50; INFLAMMATION; LIPID HOMEOSTASIS; MEDICINAL CHEMISTRY; METABOLIC BALANCE; NEOPLASM; NONHUMAN; POSITIVE FEEDBACK; PROTEIN EXPRESSION; RECEPTOR BINDING; STRUCTURE ACTIVITY RELATION; TUMOR GROWTH; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; METABOLIC DISEASES; METABOLISM;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; HUMANS; METABOLIC DISEASES; MODELS, MOLECULAR; PHARMACEUTICAL PREPARATIONS; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 84925849843     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026614666141112103516     Document Type: Article

References (121)

1. Parks, D.J.; Blanchard, S.G.; Bledsoe, R.K.; Chandra, G.; Consler, T.G.; Kliewer, S.A.; Stimmel, J.B.; Willson, T.M.; Zavacki, A.M.; Moore, D.D.; Lehmann, J.M. Bile acids: natural ligands for an orphan nuclear receptor. Science, 1999, 284(5418), 1365–1368.
2. Makishima, M.; Okamoto, A.Y.; Repa, J.J.; Tu, H.; Learned, R.M.; Luk, A.; Hull, M.V.; Lustig, K.D.; Mangelsdorf, D.J.; Shan, B. Identification of a nuclear receptor for bile acids. Science, 1999, 284(5418), 1362–1365.
3. Forman, B.M.; Goode, E.; Chen, J.; Oro, A.E.; Bradley, D.J.; Perlmann, T.; Noonan, D.J.; Burka, L.T.; McMorris, T.; Lamph, W.W.; Evans, R.M.; Weinberger, C. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell, 1995, 81(5), 687–693.
4. Seol, W.; Choi, H.S.; Moore, D.D. Isolation of proteins that interact specifically with the retinoid X receptor: two novel orphan receptors. Mol. Endocrinol., 1995, 9(1), 72–85.
5. Fiorucci, S.; Mencarelli, A.; Distrutti, E.; Zampella, A. Farnesoid X receptor: from medicinal chemistry to clinical applications. Future Med. Chem., 2012, 4(7), 877–891.
6. Fiorucci, S.; Cipriani, S.; Baldelli, F.; Mencarelli, A. Bile acidactivated receptors in the treatment of dyslipidemia and related disorders. Progress in Lipid Research, 2010, 49(2), 171–185.
7. Claudel, T.; Staels, B.; Kuipers, F. The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism. Arterioscler. Thromb. Vasc. Biol., 2005, 25(10), 2020–2030.
8. Cariou, B.; Staels, B. FXR: a promising target for the metabolic syndrome? Trends Pharmacol. Sci., 2007, 28(5), 236–243.
9. Gadaleta, R.M.; van Erpecum, Karel J; Oldenburg, B.; Willemsen, Ellen C L; Renooij, W.; Murzilli, S.; Klomp, Leo W J; Siersema, P.D.; Schipper, Marguerite, E I; Danese, S.; Penna, G.; Laverny, G.; Adorini, L.; Moschetta, A.; vanMil, Saskia W C. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut, 2011, 60(4), 463–472.
10. Düfer, M.; Hörth, K.; Krippeit-Drews, P.; Drews, G. The significance of the nuclear farnesoid X receptor (FXR) in cell function. Islets, 2012, 4(5), 333–338.
11. Adorini, L.; Pruzanski, M.; Shapiro, D. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. Drug Discov. Today, 2012, 17(17-18), 988–997.
12. Mudaliar, S.; Henry, R.R.; Sanyal, A.J.; Morrow, L.; Marschall, H.-U.; Kipnes, M.; Adorini, L.; Sciacca, C.I.; Clopton, P.; Castelloe, E.; Dillon, P.; Pruzanski, M.; Shapiro, D. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology, 2013, 145(3), 574-82.e1.
13. Li, Y.; Jadhav, K.; Zhang, Y. Bile acid receptors in non-alcoholic fatty liver disease. Biochem. Pharmacol., 2013, 86(11), 1517–1524.
14. Li, G.; Kong, B.; Zhu, Y.; Le Zhan; Williams, J.A.; Tawfik, O.; Kassel, K.M.; Luyendyk, J.P.; Wang, L.; Guo, G.L. Small heterodimer partner overexpression partially protects against liver tumor development in farnesoid X receptor knockout mice. Toxicol. Appl. Pharmacol., 2013, 272(2), 299–305.
15. Zimber, A.; Gespach, C. Bile acids and derivatives, their nuclear receptors FXR, PXR and ligands: role in health and disease and their therapeutic potential. Anticancer Agents Med. Chem., 2008, 8(5), 540–563.
16. Koutsounas, I.; Giaginis, C.; Theocharis, S. Farnesoid X Receptor (FXR) from normal to malignant state. Histol. Histopathol., 2012, 27(7), 835–853.
17. Wang, X.; Fu, X.; van Ness, C.; Meng, Z.; Ma, X.; Huang, W. Bile Acid Receptors and Liver Cancer. Curr. Pathobiol. Rep., 2013, 1(1), 29–35.
18. Gadaleta, R.M.; Cariello, M.; Sabbà, C.; Moschetta, A. Tissuespecific actions of FXR in metabolism and cancer. Biochim. Biophys. Acta, 2014.
19. Merk, D.; Steinhilber, D.; Schubert-Zsilavecz, M. Medicinal chemistry of farnesoid X receptor ligands: from agonists and antagonists to modulators. Future Med. Chem., 2012, 4(8), 1015–1036.
20. Savkur, R.S.; Thomas, J.S.; Bramlett, K.S.; Gao, Y.; Michael, L.F.; Burris, T.P. Ligand-dependent coactivation of the human bile acid receptor FXR by the peroxisome proliferator-activated receptor gamma coactivator-1alpha. J. Pharmacol. Exp. Ther., 2005, 312(1), 170–178.
21. Fiorucci, S.; Mencarelli, A.; Distrutti, E.; Palladino, G.; Cipriani, S. Targetting farnesoid-X-receptor: from medicinal chemistry to disease treatment. Curr. Med. Chem., 2010, 17(2), 139–159.
22. Germain, P.; Staels, B.; Dacquet, C.; Spedding, M.; Laudet, V. Overview of nomenclature of nuclear receptors. Pharmacol. Rev., 2006, 58(4), 685–704.
23. Di Leva, Francesco Saverio; Festa, C.; D’Amore, C.; Marino, S. de; Renga, B.; D’Auria, M.V.; Novellino, E.; Limongelli, V.; Zampella, A.; Fiorucci, S. Binding Mechanism of the Farnesoid X Receptor Marine Antagonist Suvanine Reveals a Strategy To Forestall Drug Modulation on Nuclear Receptors. Design, Synthesis, and Biological Evaluation of Novel Ligands. J. Med. Chem., 2013, 56(11), 4701–4717.
24. Kainuma, M.; Makishima, M.; Hashimoto, Y.; Miyachi, H. Design, synthesis, and evaluation of non-steroidal farnesoid X receptor (FXR) antagonist. Bioorg. Med. Chem., 2007, 15(7), 2587–2600.
25. Cui, J. Guggulsterone Is a Farnesoid X Receptor Antagonist in Coactivator Association Assays but Acts to Enhance Transcription of Bile Salt Export Pump. J. Biol. Chem., 2003, 278(12), 10214–10220.
26. Gronemeyer, H.; Gustafsson, J.-A.; Laudet, V. Principles for modulation of the nuclear receptor superfamily. Nat. Rev. Drug. Discov., 2004, 3(11), 950–964.
27. Yu, J.; Lo, J.-L.; Huang, L.; Zhao, A.; Metzger, E.; Adams, A.; Meinke, P.T.; Wright, S.D.; Cui, J. Lithocholic acid decreases expression of bile salt export pump through farnesoid X receptor antagonist activity. J. Biol. Chem., 2002, 277(35), 31441–31447.
28. Campana, G.; Pasini, P.; Roda, A.; Spampinato, S. Regulation of ileal bile acid-binding protein expression in Caco-2 cells by ursodeoxycholic acid: role of the farnesoid X receptor. Biochem. Pharmacol., 2005, 69(12), 1755–1763.
29. Hu, X.; Bonde, Y.; Eggertsen, G.; Rudling, M. Muricholic bile acids are potent regulators of bile acid synthesis via a positive feedback mechanism. J. Intern. Med., 2014, 275(1), 27–38.
30. Sayin, S.I.; Wahlström, A.; Felin, J.; Jäntti, S.; Marschall, H.-U.; Bamberg, K.; Angelin, B.; Hyötyläinen, T.; Orei, M.; Bäckhed, F. Gut Microbiota Regulates Bile Acid Metabolism by Reducing the Levels of Tauro-beta-muricholic Acid, a Naturally Occurring FXR Antagonist. Cell Metab., 2013, 17(2), 225–235.
31. Marino, S.de; Ummarino, R.; D’Auria, M.V.; Chini, M.G.; Bifulco, G.; D’Amore, C.; Renga, B.; Mencarelli, A.; Petek, S.; Fiorucci, S.; Zampella, A. 4-Methylenesterols from Theonella swinhoei sponge are natural pregnane-X-receptor agonists and farnesoid- X-receptor antagonists that modulate innate immunity. Steroids, 2012, 77(5), 484–495.
32. Renga, B.; Mencarelli, A.; D'Amore, C.; Cipriani, S.; D'Auria, M.V.; Sepe, V.; Chini, M.G.; Monti, M.C.; Bifulco, G.; Zampella, A.; Fiorucci, S.; Lobaccaro, J.-M.A. Discovery That Theonellasterol a Marine Sponge Sterol Is a Highly Selective FXR Antagonist That Protects against Liver Injury in Cholestasis. PLoS ONE, 2012, 7(1), e30443.
33. Sepe, V.; Ummarino, R.; D'Auria, M.; Taglialatela-Scafati, O.; Marino, S.; D'Amore, C.; Renga, B.; Chini, M.; Bifulco, G.; Nakao, Y.; Fusetani, N.; Fiorucci, S.; Zampella, A. Preliminary Structure- Activity Relationship on Theonellasterol, a New Chemotype of FXR Antagonist, from the Marine Sponge Theonella swinhoei. Marine Drugs, 2012, 10(12), 2448–2466.
34. Sepe, V.; Bifulco, G.; Renga, B.; D’Amore, C.; Fiorucci, S.; Zampella, A. Discovery of Sulfated Sterols from Marine Invertebrates as a New Class of Marine Natural Antagonists of Farnesoid-XReceptor. J. Med. Chem., 2011, 54(5), 1314–1320.
35. Nam, S.-J.; Ko, H.; Shin, M.; Ham, J.; Chin, J.; Kim, Y.; Kim, H.; Shin, K.; Choi, H.; Kang, H. Farnesoid X-activated receptor antagonists from a marine sponge Spongia sp. Bioorg. Med. Chem. Lett., 2006, 16(20), 5398–5402.
36. Nam, S.-J.; Ko, H.; Ju, M.K.; Hwang, H.; Chin, J.; Ham, J.; Lee, B.; Lee, J.; Won, D.H.; Choi, H.; Ko, J.; Shin, K.; Oh, T.; Kim, S.; Rho, J.-R.; Kang, H. Scalarane Sesterterpenes from a Marine Sponge of the Genus Spongia and Their FXR Antagonistic Activity. J. Nat. Prod., 2007, 70(11), 1691–1695.
37. Putra, M.Y.; Bavestrello, G.; Cerrano, C.; Renga, B.; D’Amore, C.; Fiorucci, S.; Fattorusso, E.; Taglialatela-Scafati, O. Polyhydroxylated sterols from the Indonesian soft coral Sinularia sp. and their effect on farnesoid X-activated receptor. Steroids, 2012, 77(5), 433–440.
38. Shin, K.; Chin, J.; Hahn, D.; Lee, J.; Hwang, H.; Won, D.H.; Ham, J.; Choi, H.; Kang, E.; Kim, H.; Ju, M.K.; Nam, S.-J.; Kang, H. Sterols from a soft coral, Dendronephthya gigantea as farnesoid Xactivated receptor antagonists. Steroids, 2012, 77(5), 355–359.
39. Carter, B.A.; Taylor, O.A.; Prendergast, D.R.; Zimmerman, T.L.; Furstenberg, R. von; Moore, D.D.; Karpen, S.J. Stigmasterol, a soy lipid-derived phytosterol, is an antagonist of the bile acid nuclear receptor FXR. Pediatr. Res., 2007, 62(3), 301–306.
40. Urizar, N.L. A Natural Product That Lowers Cholesterol As an Antagonist Ligand for FXR. Science, 2002, 296(5573), 1703–1706.
41. Wu, J.; Xia, C.; Meier, J.; Li, S.; Hu, X.; Lala, D.S. The hypolipidemic natural product guggulsterone acts as an antagonist of the bile acid receptor. Mol. Endocrinol., 2002, 16(7), 1590–1597.
42. Yang, L.; Broderick, D.; Jiang, Y.; Hsu, V.; Maier, C.S. Conformational dynamics of human FXR-LBD ligand interactions studied by hydrogen/deuterium exchange mass spectrometry: insights into the antagonism of the hypolipidemic agent Z-guggulsterone. Biochim. Biophys. Acta, 2014, 1844(9), 1684–1693.
43. Meyer, U.; Costantino, G.; Macchiarulo, A.; Pellicciari, R. Is antagonism of E/Z-guggulsterone at the farnesoid X receptor mediated by a noncanonical binding site? A molecular modeling study. J. Med. Chem., 2005, 48(22), 6948–6955.
44. Owsley, E.; Chiang, John Y L. Guggulsterone antagonizes farnesoid X receptor induction of bile salt export pump but activates pregnane X receptor to inhibit cholesterol 7alpha-hydroxylase gene. Biochem. Biophys. Res. Commun., 2003, 304(1), 191–195.
45. Burris, T.P.; Montrose, C.; Houck, K.A.; Osborne, H.E.; Bocchinfuso, W.P.; Yaden, B.C.; Cheng, C.C.; Zink, R.W.; Barr, R.J.; Hepler, C.D.; Krishnan, V.; Bullock, H.A.; Burris, L.L.; Galvin, R.J.; Bramlett, K.; Stayrook, K.R. The hypolipidemic natural product guggulsterone is a promiscuous steroid receptor ligand. Mol. Pharmacol., 2005, 67(3), 948–954.
46. Deng, R. Therapeutic effects of guggul and its constituent guggulsterone: cardiovascular benefits. Cardiovasc. Drug Rev., 2007, 25(4), 375–390.
47. Shishodia, S.; Sethi, G.; Ahn, K.S.; Aggarwal, B.B. Guggulsterone inhibits tumor cell proliferation, induces S-phase arrest, and promotes apoptosis through activation of c-Jun N-terminal kinase, suppression of Akt pathway, and downregulation of antiapoptotic gene products. Biochem. Pharmacol., 2007, 74(1), 118–130.
48. Xiao, D.; Singh, S.V. z-Guggulsterone, a constituent of Ayurvedic medicinal plant Commiphora mukul, inhibits angiogenesis in vitro and in vivo. Mol. Cancer Ther., 2008, 7(1), 171–180.
49. Macha, M.A.; Rachagani, S.; Gupta, S.; Pai, P.; Ponnusamy, M.P.; Batra, S.K.; Jain, M. Guggulsterone decreases proliferation and metastatic behavior of pancreatic cancer cells by modulating JAK/STAT and Src/FAK signaling. Cancer Lett., 2013, 341(2), 166–177.
50. Kumar, D.; Khanna, A.K.; Pratap, R.; Sexana, J.K.; Bhatta, R.S. Dose escalation pharmacokinetics and lipid lowering activity of a novel farnesoid X receptor modulator: 16-Dehydropregnenolone. Indian J. Pharmacol, 2012, 44(1), 57–62.
51. Xu, X.; Lu, Y.; Chen, L.; Chen, J.; Luo, X.; Shen, X. Identification of 15d-PGJ2 as an antagonist of farnesoid X receptor: Molecular modeling with biological evaluation. Steroids, 2013, 78(9), 813–822.
52. Choi, H.; Hwang, H.; Chin, J.; Kim, E.; Lee, J.; Nam, S.-J.; Lee, B.C.; Rho, B.J.; Kang, H. Tuberatolides, Potent FXR Antagonists from the Korean Marine Tunicate Botryllus tuberatus. J. Nat. Prod., 2011, 74(1), 90–94.
53. Liu, P.; Xu, X.; Chen, L.; Ma, L.; Shen, X.; Hu, L. Discovery and SAR study of hydroxyacetophenone derivatives as potent, nonsteroidal farnesoid X receptor (FXR) antagonists. Bioorg. Med. Chem., 2014, 22(5), 1596–1607.
54. Huang, H.; Yu, Y.; Gao, Z.; Zhang, Y.; Li, C.; Xu, X.; Jin, H.; Yan, W.; Ma, R.; Zhu, J.; Shen, X.; Jiang, H.; Chen, L.; Li, J. Discovery and Optimization of 1,3,4-Trisubstituted-pyrazolone Derivatives as Novel, Potent, and Nonsteroidal Farnesoid X Receptor (FXR) Selective Antagonists. J. Med. Chem., 2012, 55(16), 7037–7053.
55. Fu, J.; Si, P.; Zheng, M.; Chen, L.; Shen, X.; Tang, Y.; Li, W. Discovery of new non-steroidal FXR ligands via a virtual screening workflow based on Phase shape and induced fit docking. Bioorg. Med. Chem. Lett., 2012, 22(22), 6848–6853.
56. Yu, D.D.; Lin, W.; Forman, B.M.; Chen, T. Identification of trisubstituted- pyrazol carboxamide analogs as novel and potent antagonists of farnesoid X receptor. Bioorg. Med. Chem., 2014, 22(11), 2919–2938.
57. Komm, B.S.; Mirkin, S. An overview of current and emerging SERMs. J. Steroid Biochem. Mol. Biol., 2014, 143, 207–222.
58. Dussault, I.; Beard, R.; Lin, M.; Hollister, K.; Chen, J.; Xiao, J.-H.; Chandraratna, R.; Forman, B.M. Identification of gene-selective modulators of the bile acid receptor FXR. J. Biol. Chem., 2003, 278(9), 7027–7033.
59. Sayin, S.I.; Wahlström, A.; Felin, J.; Jäntti, S.; Marschall, H.-U.; Bamberg, K.; Angelin, B.; Hyötyläinen, T.; Orei, M.; Bäckhed, F. Gut Microbiota Regulates Bile Acid Metabolism by Reducing the Levels of Tauro-beta-muricholic Acid, a Naturally Occurring FXR Antagonist. Cell Metab., 2013, 17(2), 225–235.
60. Qi, Y.; Jiang, C.; Cheng, J.; Krausz, K.W.; Li, T.; Ferrell, J.M.; Gonzalez, F.J.; Chiang, J.Y. Bile acid signaling in lipid metabolism: Metabolomic and lipidomic analysis of lipid and bile acid markers linked to anti-obesity and anti-diabetes in mice. Biochim. Biophys. Acta, 2014, doi:10.1016/j.bbalip.2014.04.008
61. Aron-Wisnewsky, J.; Gaborit, B.; Dutour, A.; Clement, K. Gut microbiota and non-alcoholic fatty liver disease: new insights. Clin. Microbiol. Infect., 2013, 19(4), 338–348.
62. Stedman, C.; Liddle, C.; Coulter, S.; Sonoda, J.; Alvarez, J.G.; Evans, R.M.; Downes, M. Benefit of farnesoid X receptor inhibition in obstructive cholestasis. Proc. Natl. Acad. Sci. U.S.A., 2006, 103(30), 11323–11328.
63. Wang, C.; Zhang, F.; Wang, L.; Zhang, Y.; Li, X.; Huang, K.; Du, M.; Liu, F.; Huang, S.; Guan, Y.; Huang, D. Poly(ADP-Ribose) Polymerase 1 Promotes Oxidative-Stress-Induced Liver Cell Death via Suppressing Farnesoid X Receptor. Mol. Cell. Biol., 2013, 33(22), 4492–4503.
64. Dai, J.; Wang, H.; Shi, Y.; Dong, Y.; Zhang, Y.; Wang, J. Impact of bile acids on the growth of human cholangiocarcinoma via FXR. J. Hematol. Oncol., 2011, 4(1), 41.
65. Meng, Z.; Wang, Y.; Wang, L.; Jin, W.; Liu, N.; Pan, H.; Liu, L.; Wagman, L.; Forman, B.M.; Huang, W. FXR regulates liver repair after CCl4-induced toxic injury. Mol. Endocrinol., 2010, 24(5), 886–897.
66. Gottardi, A.de; Dumonceau, J.-M.; Bruttin, F.; Vonlaufen, A.; Morard, I.; Spahr, L.; Rubbia-Brandt, L.; Frossard, J.-L.; Dinjens, Winand N M; Rabinovitch, P.S.; Hadengue, A. Expression of the bile acid receptor FXR in Barrett's esophagus and enhancement of apoptosis by guggulsterone in vitro. Mol. Cancer, 2006, 5, 48.
67. Capello, A.; Moons, Leon M. G.; Van de Winkel, Anouk; Siersema, P.D.; van Dekken, H.; Kuipers, E.J.; Kusters, J.G. Bile Acid-Stimulated Expression of the Farnesoid X Receptor Enhances the Immune Response in Barrett Esophagus. Am. J. Gastroenterology, 2008, 103(6), 1510–1516.
68. Guan, B.; Li, H.; Yang, Z.; Hoque, A.; Xu, X. Inhibition of farnesoid X receptor controls esophageal cancer cell growth in vitro and in nude mouse xenografts. Cancer, 2013, 119(7), 1321–1329.
69. Düfer, M.; Horth, K.; Wagner, R.; Schittenhelm, B.; Prowald, S.; Wagner, T. F. J.; Oberwinkler, J.; Lukowski, R.; Gonzalez, F.J.; Krippeit-Drews, P.; Drews, G. Bile Acids Acutely Stimulate Insulin Secretion of Mouse ß-Cells via Farnesoid X Receptor Activation and KATP Channel Inhibition. Diabetes, 2012, 61(6), 1479–1489.
70. Rizzo, G.; Disante, M.; Mencarelli, A.; Renga, B.; Gioiello, A.; Pellicciari, R.; Fiorucci, S. The farnesoid X receptor promotes adipocyte differentiation and regulates adipose cell function in vivo. Mol. Pharmacol., 2006, 70(4), 1164–1173.
71. Id Boufker, H.; Lagneaux, L.; Fayyad-Kazan, H.; Badran, B.; Najar, M.; Wiedig, M.; Ghanem, G.; Laurent, G.; Body, J.-J.; Journé, F. Role of farnesoid X receptor (FXR) in the process of differentiation of bone marrow stromal cells into osteoblasts. Bone, 2011, 49(6), 1219–1231.
72. Scholtes, C.; Diaz, O.; Icard, V.; Kaul, A.; Bartenschlager, R.; Lotteau, V.; André, P. Enhancement of genotype 1 hepatitis C virus replication by bile acids through FXR. J. Hepatol., 2008, 48(2), 192–199.
73. Lebovics, E.; Seif, F.; Kim, D.; Elhosseiny, A.; Dworkin, B.M.; Casellas, A.; Clark, S.; Rosenthal, W.S. Pruritus in chronic hepatitis C: association with high serum bile acids, advanced pathology, and bile duct abnormalities. Dig. Dis. Sci., 1997, 42(5), 1094–1099.
74. Mencarelli, A.; Renga, B.; Migliorati, M.; Cipriani, S.; Distrutti, E.; Santucci, L.; Fiorucci, S. The bile acid sensor farnesoid X receptor is a modulator of liver immunity in a rodent model of acute hepatitis. J. Immunol., 2009, 183(10), 6657–6666.
75. Lee, J.Y.; Lee, K.T.; Lee, J.K.; Lee, K.H.; Jang, K.-T.; Heo, J.S.; Choi, S.H.; Kim, Y.; Rhee, J.C. Farnesoid X receptor, overexpressed in pancreatic cancer with lymph node metastasis promotes cell migration and invasion. Br. J. Cancer, 2011, 104(6), 1027–1037.
76. Gottardi, A.de; Touri, F.; Maurer, C.A.; Perez, A.; Maurhofer, O.; Ventre, G.; Bentzen, C.L.; Niesor, E.J.; Dufour, J.-F. The bile acid nuclear receptor FXR and the bile acid binding protein IBABP are differently expressed in colon cancer. Dig. Dis. Sci., 2004, 49(6), 982–989.
77. Journe, F.; Durbecq, V.; Chaboteaux, C.; Rouas, G.; Laurent, G.; Nonclercq, D.; Sotiriou, C.; Body, J.-J.; Larsimont, D. Association between farnesoid X receptor expression and cell proliferation in estrogen receptor-positive luminal-like breast cancer from postmenopausal patients. Breast Cancer Res. Treat., 2009, 115(3), 523–535.
78. Swales, K.E.; Korbonits, M.; Carpenter, R.; Walsh, D.T.; Warner, T.D.; Bishop-Bailey, D. The farnesoid X receptor is expressed in breast cancer and regulates apoptosis and aromatase expression. Cancer Res., 2006, 66(20), 10120–10126.
79. Silva, J.; Dasgupta, S.; Wang, G.; Krishnamurthy, K.; Ritter, E.; Bieberich, E. Lipids isolated from bone induce the migration of human breast cancer cells. J. Lipid Res., 2006, 47(4), 724–733.
80. Ohno, T.; Shirakami, Y.; Shimizu, M.; Kubota, M.; Sakai, H.; Yasuda, Y.; Kochi, T.; Tsurumi, H.; Moriwaki, H. Synergistic growth inhibition of human hepatocellular carcinoma cells by acyclic retinoid and GW4064, a farnesoid X receptor ligand. Cancer Lett., 2012, 323(2), 215–222.
81. Maran, Rengasamy R M; Thomas, A.; Roth, M.; Sheng, Z.; Esterly, N.; Pinson, D.; Gao, X.; Zhang, Y.; Ganapathy, V.; Gonzalez, F.J.; Guo, G.L. Farnesoid X receptor deficiency in mice leads to increased intestinal epithelial cell proliferation and tumor development. J. Pharmacol. Exp. Ther., 2009, 328(2), 469–477.
82. Modica, S.; Murzilli, S.; Salvatore, L.; Schmidt, D.R.; Moschetta, A. Nuclear bile acid receptor FXR protects against intestinal tumorigenesis. Cancer Res., 2008, 68(23), 9589–9594.
83. Van Dijk, Theo H; Grefhorst, A.; Oosterveer, M.H.; Bloks, V.W.; Staels, B.; Reijngoud, D.-J.; Kuipers, F. An increased flux through the glucose 6-phosphate pool in enterocytes delays glucose absorption in Fxr-/- mice. J. Biol. Chem., 2009, 284(16), 10315–10323.
84. Kok, T.; Hulzebos, C.V.; Wolters, H.; Havinga, R.; Agellon, L.B.; Stellaard, F.; Shan, B.; Schwarz, M.; Kuipers, F. Enterohepatic circulation of bile salts in farnesoid X receptor-deficient mice: effi cient intestinal bile salt absorption in the absence of ileal bile acidbinding protein. J. Biol. Chem., 2003, 278(43), 41930–41937.
85. Lambert, G.; Amar, Marcelo J A; Guo, G.; Brewer, H.B.; Gonzalez, F.J.; Sinal, C.J. The farnesoid X-receptor is an essential regulator of cholesterol homeostasis. J. Biol. Chem., 2003, 278(4), 2563–2570.
86. Ma, K.; Saha, P.K.; Chan, L.; Moore, D.D. Farnesoid X receptor is essential for normal glucose homeostasis. J. Clin. Invest., 2006, 116(4), 1102–1109.
87. Sinal, C.J.; Tohkin, M.; Miyata, M.; Ward, J.M.; Lambert, G.; Gonzalez, F.J. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell, 2000, 102(6), 731–744.
88. Zhang, Y.; Ge, X.; Heemstra, L.A.; Chen, W.-D.; Xu, J.; Smith, J.L.; Ma, H.; Kasim, N.; Edwards, P.A.; Novak, C.M. Loss of FXR protects against diet-induced obesity and accelerates liver carcinogenesis in ob/ob mice. Mol. Endocrinol., 2012, 26(2), 272–280.
89. Zhang, Y.; Lee, F.Y.; Barrera, G.; Lee, H.; Vales, C.; Gonzalez, F.J.; Willson, T.M.; Edwards, P.A. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc. Natl. Acad. Sci. U.S.A., 2006, 103(4), 1006–1011.
90. Zhang, Y.; Wang, X.; Vales, C.; Lee, F.Y.; Lee, H.; Lusis, A.J.; Edwards, P.A. FXR deficiency causes reduced atherosclerosis in Ldlr-/- mice. Arterioscler. Thromb. Vasc. Biol., 2006, 26(10), 2316–2321.
91. Cariou, B.; Bouchaert, E.; Abdelkarim, M.; Dumont, J.; Caron, S.; Fruchart, J.-C.; Burcelin, R.; Kuipers, F.; Staels, B. FXRdeficiency confers increased susceptibility to torpor. FEBS Lett., 2007, 581(27), 5191–5198.
92. Cariou, B.; van Harmelen, K.; Duran-Sandoval, D.; van Dijk, T.; Grefhorst, A.; Bouchaert, E.; Fruchart, J.-C.; Gonzalez, F.J.; Kuipers, F.; Staels, B. Transient impairment of the adaptive response to fasting in FXR-deficient mice. FEBS Lett., 2005, 579(19), 4076–4080.
93. Cariou, B.; van Harmelen, K.; Duran-Sandoval, D.; van Dijk, Theo H; Grefhorst, A.; Abdelkarim, M.; Caron, S.; Torpier, G.; Fruchart, J.-C.; Gonzalez, F.J.; Kuipers, F.; Staels, B. The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J. Biol. Chem., 2006, 281(16), 11039–11049.
94. Kim, I.; Morimura, K.; Shah, Y.; Yang, Q.; Ward, J.M.; Gonzalez, F.J. Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice. Carcinogenesis, 2007, 28(5), 940–946.
95. Yang, F.; Huang, X.; Yi, T.; Yen, Y.; Moore, D.D.; Huang, W. Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. Cancer Res., 2007, 67(3), 863–867.
96. Lian, F.; Xing, X.; Yuan, G.; Schäfer, C.; Rauser, S.; Walch, A.; Röcken, C.; Ebeling, M.; Wright, M.B.; Schmid, R.M.; Ebert, Matthias P A; Burgermeister, E. Farnesoid X receptor protects human and murine gastric epithelial cells against inflammation-induced damage. Biochem. J., 2011, 438(2), 315–323.
97. Prawitt, J.; Abdelkarim, M.; Stroeve, Johanna H M; Popescu, I.; Duez, H.; Velagapudi, V.R.; Dumont, J.; Bouchaert, E.; van Dijk, Theo H; Lucas, A.; Dorchies, E.; Daoudi, M.; Lestavel, S.; Gonzalez, F.J.; Oresic, M.; Cariou, B.; Kuipers, F.; Caron, S.; Staels, B. Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity. Diabetes, 2011, 60(7), 1861–1871.
98. Wang, X.X.; Jiang, T.; Shen, Y.; Caldas, Y.; Miyazaki-Anzai, S.; Santamaria, H.; Urbanek, C.; Solis, N.; Scherzer, P.; Lewis, L.; Gonzalez, F.J.; Adorini, L.; Pruzanski, M.; Kopp, J.B.; Verlander, J.W.; Levi, M. Diabetic nephropathy is accelerated by farnesoid X receptor deficiency and inhibited by farnesoid X receptor activation in a type 1 diabetes model. Diabetes, 2010, 59(11), 2916–2927.
99. Kong, B.; Luyendyk, J.P.; Tawfik, O.; Guo, G.L. Farnesoid X receptor deficiency induces nonalcoholic steatohepatitis in lowdensity lipoprotein receptor-knockout mice fed a high-fat diet. J. Pharmacol. Exp. Ther., 2009, 328(1), 116–122.
100. Duran-Sandoval, D.; Cariou, B.; Percevault, F.; Hennuyer, N.; Grefhorst, A.; van Dijk, Theo H; Gonzalez, F.J.; Fruchart, J.-C.; Kuipers, F.; Staels, B. The farnesoid X receptor modulates hepatic carbohydrate metabolism during the fasting-refeeding transition. J. Biol. Chem., 2005, 280(33), 29971–29979.
101. Hanniman, E.A.; Lambert, G.; McCarthy, T.C.; Sinal, C.J. Loss of functional farnesoid X receptor increases atherosclerotic lesions in apolipoprotein E-deficient mice. J. Lipid Res., 2005, 46(12), 2595–2604.
102. Guo, G.L.; Santamarina-Fojo, S.; Akiyama, T.E.; Amar, Marcelo J A; Paigen, B.J.; Brewer, B.; Gonzalez, F.J. Effects of FXR in foam-cell formation and atherosclerosis development. Biochim. Biophys. Acta, 2006, 1761(12), 1401–1409.
103. Mencarelli, A.; Renga, B.; Distrutti, E.; Fiorucci, S. Antiatherosclerotic effect of farnesoid X receptor. Am. J. Physiol. Heart Circ. Physiol., 2009, 296(2), H272-81.
104. Nomoto, M.; Miyata, M.; Yin, S.; Kurata, Y.; Shimada, M.; Yoshinari, K.; Gonzalez, F.J.; Suzuki, K.; Shibasaki, S.; Kurosawa, T.; Yamazoe, Y. Bile acid-induced elevated oxidative stress in the absence of farnesoid X receptor. Biol. Pharm. Bull., 2009, 32(2), 172–178.
105. Abdelkarim, M.; Caron, S.; Duhem, C.; Prawitt, J.; Dumont, J.; Lucas, A.; Bouchaert, E.; Briand, O.; Brozek, J.; Kuipers, F.; Fievet, C.; Cariou, B.; Staels, B. The farnesoid X receptor regulates adipocyte differentiation and function by promoting peroxisome proliferator-activated receptor-gamma and interfering with the Wnt/beta-catenin pathways. J. Biol. Chem., 2010, 285(47), 36759–36767.
106. Wolfe, A.; Thomas, A.; Edwards, G.; Jaseja, R.; Guo, G.L.; Apte, U. Increased activation of the Wnt/beta-catenin pathway in spontaneous hepatocellular carcinoma observed in farnesoid X receptor knockout mice. J. Pharmacol. Exp. Ther., 2011, 338(1), 12–21.
107. Vavassori, P.; Mencarelli, A.; Renga, B.; Distrutti, E.; Fiorucci, S. The bile acid receptor FXR is a modulator of intestinal innate immunity. J. Immunol., 2009, 183(10), 6251–6261.
108. Hartman, H.B.; Lai, K.; Evans, M.J. Loss of small heterodimer partner expression in the liver protects against dyslipidemia. J. Lipid Res., 2008, 50(2), 193–203.
109. Bjursell, M.; Wedin, M.; Admyre, T.; Hermansson, M.; Bottcher, G.; Goransson, M.; Linden, D.; Bamberg, K.; Oscarsson, J.; Bohlooly-Y, M. Ageing Fxr deficient mice develop increased energy expenditure, improved glucose control and liver damage resembling NASH. PLoS One, 2013, 8(5), e64721.
110. Schuetz, E.G.; Strom, S.; Yasuda, K.; Lecureur, V.; Assem, M.; Brimer, C.; Lamba, J.; Kim, R.B.; Ramachandran, V.; Komoroski, B.J.; Venkataramanan, R.; Cai, H.; Sinal, C.J.; Gonzalez, F.J.; Schuetz, J.D. Disrupted Bile Acid Homeostasis Reveals an Unexpected Interaction among Nuclear Hormone Receptors, Transporters, and Cytochrome P450. J. Biol. Chem., 2001, 276(42), 39411–39418.
111. Kim, I.; Ahn, S.-H.; Inagaki, T.; Choi, M.; Ito, S.; Guo, G.L.; Kliewer, S.A.; Gonzalez, F.J. Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine. J. Lipid Res., 2007, 48(12), 2664–2672.
112. Moschetta, A.; Bookout, A.L.; Mangelsdorf, D.J. Prevention of cholesterol gallstone disease by FXR agonists in a mouse model. Nat. Med., 2004, 10(12), 1352–1358.
113. Watanabe, M.; Houten, S.M.; Wang, L.; Moschetta, A.; Mangelsdorf, D.J.; Heyman, R.A.; Moore, D.D.; Auwerx, J. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J. Clin. Invest., 2004, 113(10), 1408–1418.
114. Inagaki, T.; Moschetta, A.; Lee, Y.-K.; Peng, L.; Zhao, G.; Downes, M.; Yu, R.T.; Shelton, J.M.; Richardson, J.A.; Repa, J.J.; Mangelsdorf, D.J.; Kliewer, S.A. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc. Natl. Acad. Sci. U.S.A., 2006, 103(10), 3920–3925.
115. Wu, W.; Liu, X.; Peng, X.; Xue, R.; Ji, L.; Shen, X.; Chen, S.; Gu, J.; Zhang, S. Bile acids override steatosis in farnesoid X receptor deficient mice in a model of non-alcoholic steatohepatitis. Biochem. Biophys. Res. Commun., 2014, 448(1), 50–55.
116. Ueda, J.; Chijiiwa, K.; Nakano, K.; Zhao, G.; Tanaka, M. Lack of intestinal bile results in delayed liver regeneration of normal rat liver after hepatectomy accompanied by impaired cyclin Eassociated kinase activity. Surgery, 2002, 131(5), 564–573.
117. Huang, W. Nuclear Receptor-Dependent Bile Acid Signaling Is Required for Normal Liver Regeneration. Science, 2006, 312(5771), 233–236.
118. Su, H.; Ma, C.; Liu, J.; Li, N.; Gao, M.; Huang, A.; Wang, X.; Huang, W.; Huang, X. Downregulation of nuclear receptor FXR is associated with multiple malignant clinicopathological characteris tics in human hepatocellular carcinoma. Am. J. Physiol. Gastrointest. Liver Physiol., 2012, 303(11), G1245-53.
119. Lee, J.Y.; Lee, K.T.; Lee, J.K.; Lee, K.H.; Jang, K.-T.; Heo, J.S.; Choi, S.H.; Kim, Y.; Rhee, J.C. Farnesoid X receptor, overexpressed in pancreatic cancer with lymph node metastasis promotes cell migration and invasion. Br. J. Cancer, 2011, 104(6), 1027–1037.
120. Maran, Rengasamy R M; Thomas, A.; Roth, M.; Sheng, Z.; Esterly, N.; Pinson, D.; Gao, X.; Zhang, Y.; Ganapathy, V.; Gonzalez, F.J.; Guo, G.L. Farnesoid X receptor deficiency in mice leads to increased intestinal epithelial cell proliferation and tumor development. J. Pharmacol. Exp. Ther., 2009, 328(2), 469–477.
121. Ciruelos, E.; Pascual, T.; Arroyo Vozmediano, María Luisa; Blanco, M.; Manso, L.; Parrilla, L.; Muñoz, C.; Vega, E.; Calderón, M.J.; Sancho, B.; Cortes-Funes, H. The therapeutic role of fulvestrant in the management of patients with hormone receptorpositive breast cancer. Breast, 2014, 23(3), 201–208.